SGLT2 Inhibitors for Type 2 Diabetes and CKD Management

First-Line Treatment Recommendations

• The American Diabetes Association and the Kidney Disease: Improving Global Outcomes (KDIGO) recommend SGLT2 inhibitors as the first-line drug therapy for patients with type 2 diabetes and CKD to prevent kidney disease progression and cardiovascular events, regardless of glycemic control needs 1, 2
• SGLT2 inhibitors are recommended for patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m² due to their proven kidney and cardiovascular benefits, with specific inhibitors including Canagliflozin 100 mg, Dapagliflozin 10 mg, and Empagliflozin 10 mg 1, 3, 4

Comprehensive Medication Algorithm for CKD Patients with Diabetes

• The American College of Cardiology recommends starting SGLT2 inhibitors when eGFR ≥20 mL/min/1.73 m², and Metformin can be used with eGFR ≥30 mL/min/1.73 m², with dose reduction to 1000 mg daily when eGFR is 30-44 mL/min/1.73 m² 2, 3, 5
• GLP-1 receptor agonists are recommended for patients who don't meet glycemic targets with metformin and/or SGLT2i or who cannot use these medications, particularly beneficial for patients with obesity and CKD to promote intentional weight loss 3, 6

Benefits of SGLT2 Inhibitors in CKD

• SGLT2 inhibitors reduce the risk of CKD progression and cardiovascular events, slow GFR decline, and reduce albuminuria, with benefits persisting even at lower eGFR levels (down to 20 mL/min/1.73 m²) 1, 2
• SGLT2 inhibitors provide cardiovascular protection independent of glucose-lowering effects, and reduce the risk of heart failure hospitalizations 2, 7

Practical Considerations When Initiating SGLT2 Inhibitors

• Assess hypoglycemia risk, especially if patient is on insulin or sulfonylureas, and consider reducing insulin/sulfonylurea doses when starting SGLT2i, with careful monitoring due to increased hypoglycemia risk in CKD 1
• Evaluate volume depletion risk, especially with concurrent diuretic use, and consider diuretic dose reduction if needed, with education on potential adverse effects including genital infections, diabetic ketoacidosis, and foot ulcer concerns 1, 3

Important Cautions and Contraindications

• Sulfonylureas should be used with caution due to hypoglycemia risk, and Metformin is contraindicated when eGFR <30 mL/min/1.73 m², with Exenatide (GLP-1 RA) not recommended in severe CKD 3, 4, 5
• Monitor for euglycemic ketoacidosis with SGLT2 inhibitors, particularly during illness or perioperative periods, with careful monitoring and dose adjustment due to increased hypoglycemia risk in advanced CKD 1, 8

Special Considerations for Advanced CKD

• For patients with eGFR <20 mL/min/1.73 m², GLP-1 RAs maintain glucose-lowering efficacy while SGLT2 inhibitors have diminished glycemic effects, with insulin therapy often becoming necessary but requiring careful monitoring and dose adjustment due to increased hypoglycemia risk 4, 8, 9

Safe Diabetes Medications in Chronic Kidney Disease

First-Line Medications for Diabetes in CKD

• The American Journal of Kidney Diseases recommends continuing SGLT2 inhibitors as tolerated until dialysis or transplantation is initiated in patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m² 10

Second-Line and Additional Options

• The American Journal of Kidney Diseases suggests that sulfonylureas should be used with caution due to increased hypoglycemia risk in CKD, and glipizide is the preferred agent among sulfonylureas as it does not have active metabolites 11
• The American Journal of Kidney Diseases recommends avoiding first-generation sulfonylureas (chlorpropamide, tolazamide, tolbutamide) altogether in CKD 12

Special Considerations in Advanced CKD

• The American Journal of Kidney Diseases states that the risk of hypoglycemia increases in CKD stages 4-5 due to decreased clearance of insulin and some oral agents, and impaired renal gluconeogenesis 11
• The American Journal of Kidney Diseases suggests that patients on insulin therapy may require dose reductions of 25% or more when eGFR <45 mL/min/1.73 m² 12

Comprehensive Management Approach

• The Kidney International recommends initiating RAS blockade (ACEi or ARB) in patients with diabetes, hypertension, and albuminuria 13
• The Kidney International suggests that statin therapy is recommended for all patients with diabetes and CKD 10
• The American Journal of Kidney Diseases recommends regular HbA1c monitoring every 3-6 months, with awareness that HbA1c may be less accurate in advanced CKD 11

Tirzepatide Use in CKD Stage 2 Patients

Integration with CKD Management Guidelines

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines support the use of SGLT2 inhibitors as first-line therapy for CKD patients with type 2 diabetes, with metformin as an alternative for patients with eGFR ≥60 mL/min/1.73 m² 14, 15
• The American Diabetes Association and the European Association for the Study of Diabetes recommend adding a GLP-1 receptor agonist, such as tirzepatide, to metformin and/or SGLT2 inhibitors when glycemic targets are not met 15

Practical Prescribing Considerations for CKD Stage 2

• The KDIGO guidelines recommend continuing routine annual CKD screening with spot urine ACR and eGFR for all diabetes patients, including those on tirzepatide 14
• Tirzepatide can be added to existing SGLT2 inhibitor therapy, as the KDIGO guidelines support combining GLP-1 RAs with SGLT2 inhibitors for comprehensive cardiorenal protection 15
• When starting tirzepatide, reduce doses of insulin or sulfonylureas to minimize hypoglycemia risk, as recommended by the KDIGO guidelines 15

Common Pitfalls to Avoid

• The KDIGO guidelines advise against withholding tirzepatide based solely on CKD stage 2 diagnosis, as pharmacokinetic data shows no need for dose adjustment at this level of renal function 14, 15
• The KDIGO guidelines recommend not assuming tirzepatide replaces SGLT2 inhibitors, as current guidelines prioritize SGLT2 inhibitors for proven kidney protection, and tirzepatide should be viewed as complementary therapy when additional glycemic control or weight loss is needed 14, 15

Management of Type 2 Diabetes with CKD Stage 3a

Medication Optimization

• The American Diabetes Association recommends continuing SGLT2 inhibitors, such as Jardiance, at current dose despite eGFR of 55 mL/min/1.73 m², as they provide kidney and cardiovascular protection down to eGFR 20 mL/min/1.73 m² 16
• The glucose-lowering effect of SGLT2 inhibitors is diminished at eGFR <45 mL/min/1.73 m², but the renal and cardiovascular benefits persist 16
• Metformin dose should be reduced to maximum 1000 mg daily at eGFR 55 mL/min/1.73 m², and monitor eGFR every 3-6 months, discontinuing metformin if eGFR falls below 30 mL/min/1.73 m² 16
• Consider transitioning from 70/30 premixed insulin to basal insulin only, such as glargine, detemir, or degludec, to reduce complexity and hypoglycemia risk 17, 18

Critical Monitoring Requirements

• Monitor eGFR and urine albumin-to-creatinine ratio every 3-6 months to track CKD progression and adjust medications accordingly 16
• Temporarily discontinue metformin during acute illness, hospitalizations, or before procedures with iodinated contrast 16, 17
• Target blood pressure <140/90 mmHg, though individualized targets may be appropriate 16

Common Pitfalls to Avoid

• Never stop Jardiance based solely on reduced glucose-lowering effect at eGFR 55, as the primary benefit at this stage is cardiorenal protection, not glycemic control 16
• Do not add sulfonylureas to the regimen given the significantly increased hypoglycemia risk in CKD and the availability of safer alternatives, such as GLP-1 RAs 17
• The A1c of 7.4% with TIR 83% represents reasonable glycemic control in a patient with CKD; aggressive intensification risks hypoglycemia without proportional benefit 17, 18